Insider Selling: BioLife Solutions (NASDAQ:BLFS) EVP Sells $16,902.90 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 630 shares of the firm’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $26.83, for a total value of $16,902.90. Following the completion of the sale, the executive vice president directly owned 351,421 shares of the company’s stock, valued at approximately $9,428,625.43. This trade represents a 0.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

BioLife Solutions Stock Down 1.5%

Shares of BLFS stock opened at $25.58 on Thursday. BioLife Solutions, Inc. has a fifty-two week low of $19.10 and a fifty-two week high of $29.55. The stock has a market cap of $1.23 billion, a P/E ratio of -213.15 and a beta of 1.78. The business has a fifty day simple moving average of $23.69 and a 200-day simple moving average of $23.33.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The firm had revenue of $25.42 million during the quarter, compared to analysts’ expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

BLFS has been the subject of a number of research analyst reports. Zacks Research upgraded BioLife Solutions to a “strong-buy” rating in a research report on Monday, August 11th. HC Wainwright restated a “buy” rating and issued a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Stephens initiated coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Wall Street Zen cut BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions currently has a consensus rating of “Buy” and a consensus price target of $31.29.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently modified their holdings of BLFS. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BioLife Solutions in the 4th quarter valued at about $31,000. State of Wyoming lifted its stake in shares of BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,490 shares in the last quarter. US Bancorp DE lifted its stake in shares of BioLife Solutions by 243.7% in the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 1,528 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 441 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of BioLife Solutions by 18.6% in the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock valued at $96,000 after purchasing an additional 663 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.